Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of antiretroviral drugs,
today announces the launch of generic Favipiravir in India under the brand name ‘Favivir.’ Hetero has been granted the manufacturing and marketing approval for Favipiravir from the Drug Controller General of India (DCGI).

Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. It is an oral antiviral medication that has demonstrated positive clinical outcomes. Favivir improves treatment accessibility to a significant amount of Covid-19 patient population, which usually sustains mild to moderate symptoms.

Hetero’s Favivir is priced at Rs. 59 per tablet and is marketed and distributed by Hetero Healthcare Limited. The product is available from today at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription.

Backed by strong vertical integration capabilities, the drug is being manufactured at the world-class formulation facility in India, which has been approved by stringent global regulatory authorities such as USFDA and the EU, among others.

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products. 

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology,Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.

The company has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.